Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
German Consortium for Hereditary Breast and Ovarian Cancer, |
RCV003482187 | SCV004227973 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2023-10-12 | criteria provided, single submitter | curation | PVS1_strong, PS3_sup, PM2_sup Frameshift-variant which affects oligomerization domain and CTD. More c-terminal variants are classified pathogenic in Penkert et al., p.Ala347Pro shows only 11.3% of wild-type Transcriptional activity in yeast (Kato et al.). According to the ACMG gene specific: TP53 criteria we chose these criteria: PVS1 (strong pathogenic): Frameshift variant which affects oligomerziation domain, PS3 (supporting pathogenic): p.Ala347Pro shows only 11.3% of wild-type Transcriptional activity in yeast (Kato et al.), PM2 (supporting pathogenic): Absent from controls |